Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IHC 2021 | Flexible use of rimegepant for migraine

Christopher Jensen, PharmD, MBA, Biohaven Pharmaceuticals, New Haven, CT, talks on future research on rimegepant for migraine. Exploring the idea of a flexible treatment that works acutely and preventively would be of great benefit. This flexible dosing and efficacy provide a more complete, flexible treatment option for patients, increasing control of the disease. Moving forward, more studies investigating the flexible use of rimegepant would be valuable for patients and healthcare providers. This interview took place during the International Headache Congress 2021.


Dr Jensen is employed by and holds stock/stock options in Biohaven Pharmaceuticals